Anne Vanlent

Anne Vanlent discloses dealings in 4 companies, chiefly Ocera Therapeutics, Inc., Trevi Therapeutics, Inc. and Aegerion Pharmaceuticals, Inc. We count 6 filings; the first trade dates from 29 November 2016 and the latest from 9 May 2019.

No open-market sale appears; the market trades are 1 purchase worth €45k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 2 share grants. 2019 to date brings 1 purchase and no sales.

The latest filing, published on 13 May 2019, reports a transaction in Trevi Therapeutics, Inc. The last insider purchase was made public on 13 May 2019, 2,718 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.